Novartis (NYSE: NVS) revealed plans of acquiring Avidity Biosciences Inc (NASDAQ: RNA) in a $12 billion all-cash transaction – valuing each share of the biotech company at $72 on Monday. The announcement sent RNA shares soaring roughly 44% in a single session – indicating investor enthusiasm and confidence in the buyout terms. Meanwhile, Novartis stock











